Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Industry News

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

July 25, 2017

News Industry News

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

October 30, 2016

News Industry News

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

March 01, 2016

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Industry News

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

October 14, 2015

News Industry News

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

September 10, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

Advertisement

Abbott Initiates Clinical Trial of Three-Month Dual Antiplatelet Therapy Following Implantation with XIENCE Coronary Stent

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Polymer-Free Drug-Coated vs. Bare-Metal Coronary Stents In High Bleeding Risk Patients With One Month DAPT

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content